Navigation Links
Amcor Invests €6.7 Million in the Extension of its Singen Converting Plant in Germany
Date:6/29/2011

ZURICH, June 29, 2011 /PRNewswire/ --


 

Amcor Flexibles Europe & Americas announces the investment of €6.7 million in its Singen converting plant in Germany. This extends the capacity for the production of pharmaceutical packaging and upgrades the classic converting facility meeting the needs of the Pharmaceutical industry.

     (Logo: http://www.newscom.com/cgi-bin/prnh/20110630/465056 )

The aluminum foil rolling and converting plant, employing 1100 people, has integrated mills and supplies high quality multilayer aluminum-based packaging materials to customers all over the world in the pharmaceutical and food industries.

This investment will enlarge the Pharma Clean Center, LKM24, inaugurated three years ago, with a further production hall housing three additional reel slitting machines. Jean-Marie Bouzendorffer, General Manager of Amcor Flexibles Singen: "With this important investment Amcor improves the overall production environment to further meet our customers' growing needs."

Amcor will continue to upgrade and improve their converting capabilities. In the future, sensitive packaging will be made only in specific production areas in order to meet the high cleanliness and hygiene standards of the pharmaceutical industry.

About Amcor Flexibles Europe & Americas

With 73 plants in 23 countries, Amcor Flexibles Europe & Americas, a division of Amcor, is a market leader and the world's largest supplier of flexible packaging. We deliver innovative packaging solutions and provide enhanced quality products for the food, beverage, pharma, personal care, medical and industrial markets. Its award winning approach towards sustainability makes Amcor Flexibles Europe & Americas the preferred partner for customers looking for responsible packaging solutions. For more information visit http://www.amcor.com

About Amcor

Amcor Limited is a global leader in responsible packaging solutions, employing more than 35,000 people worldwide, operating in 43 countries across 300 sites.  Amcor supplies a broad range of plastic (rigid and flexible), fiber, metal and glass packaging solutions to enhance the products consumers use in everyday life. Amcor also provides packaging-related services that help customers succeed through collaboration and innovation driven by art and science. Amcor is headquartered in Melbourne, Australia and is listed on the Australian Securities Exchange. For more information visit http://www.amcor.com

For further information, please contact:

Ulrike Klett
Communications Manager
Amcor Flexibles Singen
Ph: +49-7-73-18-02-589
E-mail: ulrike.klett@amcor.com

Florence Rocq
Communications Manager, Global Pharma
Amcor Flexibles Europe & Americas
Ph: +33-1-57-00-37-15
E-mail: florence.rocq@amcor.com



'/>"/>
SOURCE Amcor Flexibles Europe & Americas
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Governor Corbett Announces at Least 80 New Jobs in Lehigh Valley with Pharmaceutical Companys Purchase, Renovation of Former Amcor Site
2. Kansas Invests Millions in Innovations to Improve Human Health and Launches Three National Bioscience Programs at BIO08
3. 7 Health Ventures Invests in Tulip Medical
4. Foundation Venture Capital Group Invests in UMDNJ Company Working to Improve Leukemia Treatments
5. Merial invests US $70 million in Nanchang, China
6. JumpStart Invests in Checkpoint Surgical
7. Dutch Public-Private Partnership Invests 28 Million Euro on Research Into Personalized Medicine
8. Foundation Venture Capital Group Invests in Start-Up Company Developing Blood Test to Determine Risk and Diagnose Alzheimers Disease
9. The SCOOTER Store Invests in Ethics Training for Future Doctors
10. University of Michigan Wolverine Venture Fund Invests in Delphinus Medical Technologies
11. JumpStart Ventures Invests In and Provides Entrepreneurial Assistance to Drug Development Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... April 20, 2017   ZappRx, Inc ., a digital ... prescribing process, today announced it closed $25 million in Series ... capital firm based in Seattle that ... Partners . The Series B round included participation from ... 2014, and GV (formerly Google Ventures). As part ...
(Date:4/20/2017)... -- Eyevensys, a private biotechnology company developing ... technology that enables the safe, local, sustained production of ... range of ophthalmic diseases, announces it has received approval ... (MHRA) to advance its technology into clinical development. ... The EyeCET platform ...
(Date:4/19/2017)... - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces that ... Conference 2017 at the Sheraton Hotel in Toronto, Ontario ... of the Company is scheduled to present on Tuesday, May 2 ... the Chairman of the Board, Tony Holler will also ... For more ...
Breaking Medicine Technology:
(Date:4/28/2017)... New York, NY (PRWEB) , ... April 28, ... ... Shiel Medical Laboratory to expanded distribution of the GlycoMark test throughout the Northeast ... indicates recent hyperglycemia in patients with diabetes. The GlycoMark test provides a clinically ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America proudly ... offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start and ... These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor and ...
(Date:4/28/2017)... ... April 28, 2017 , ... Datta Endoscopic Back Surgery and ... revolutionary endoscopic practice under Dr. Datta. Patel is a Board Certified Anesthesiologist, with ... revolutionary eDiscSculpt Technique created and used by Datta Endoscopic is unlike traditional back ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... The Texas ... in recently to the labor and delivery team at Women’s Hospital at Renaissance in ... who give birth at the hospital and decide to donate. , “Women’s Hospital ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... hERG liability could substantially improve drug safety and minimize the cost of development. ... validating ion channel inhibition using cell lines and for cardiac toxicity using induced ...
Breaking Medicine News(10 mins):